Cargando…
Listeria monocytogenes as a Vector for Cancer Immunotherapy
Cancer is a wide group of diseases, which was responsible for 9.6 million deaths in 2018. Cancer immunotherapies have become a reality, with the first approval for sipuleucel-T for prostate cancer therapy occurring in 2010. Listeria monocytogenes is a Gram-positive bacterium, mostly known as a food-...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563333/ https://www.ncbi.nlm.nih.gov/pubmed/32764358 http://dx.doi.org/10.3390/vaccines8030439 |
_version_ | 1783595466737319936 |
---|---|
author | Leitão, Jorge H. |
author_facet | Leitão, Jorge H. |
author_sort | Leitão, Jorge H. |
collection | PubMed |
description | Cancer is a wide group of diseases, which was responsible for 9.6 million deaths in 2018. Cancer immunotherapies have become a reality, with the first approval for sipuleucel-T for prostate cancer therapy occurring in 2010. Listeria monocytogenes is a Gram-positive bacterium, mostly known as a food-borne pathogen, capable of causing life-threatening and often fatal infections. However, since in the majority of cases the human immune system is able to mount potent innate and adaptive immune responses that control infections by Listeria monocytogenes, the microorganism has become an attractive vector for the development of cancer vaccines. The review by Flickinger Jr., Rodeck and Snook (Vaccines 2018, 6, 48) on the use of Listeria monocytogenes as a vector for cancer immunotherapy is described and commented here. |
format | Online Article Text |
id | pubmed-7563333 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75633332020-10-27 Listeria monocytogenes as a Vector for Cancer Immunotherapy Leitão, Jorge H. Vaccines (Basel) Editorial Cancer is a wide group of diseases, which was responsible for 9.6 million deaths in 2018. Cancer immunotherapies have become a reality, with the first approval for sipuleucel-T for prostate cancer therapy occurring in 2010. Listeria monocytogenes is a Gram-positive bacterium, mostly known as a food-borne pathogen, capable of causing life-threatening and often fatal infections. However, since in the majority of cases the human immune system is able to mount potent innate and adaptive immune responses that control infections by Listeria monocytogenes, the microorganism has become an attractive vector for the development of cancer vaccines. The review by Flickinger Jr., Rodeck and Snook (Vaccines 2018, 6, 48) on the use of Listeria monocytogenes as a vector for cancer immunotherapy is described and commented here. MDPI 2020-08-05 /pmc/articles/PMC7563333/ /pubmed/32764358 http://dx.doi.org/10.3390/vaccines8030439 Text en © 2020 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Editorial Leitão, Jorge H. Listeria monocytogenes as a Vector for Cancer Immunotherapy |
title | Listeria monocytogenes as a Vector for Cancer Immunotherapy |
title_full | Listeria monocytogenes as a Vector for Cancer Immunotherapy |
title_fullStr | Listeria monocytogenes as a Vector for Cancer Immunotherapy |
title_full_unstemmed | Listeria monocytogenes as a Vector for Cancer Immunotherapy |
title_short | Listeria monocytogenes as a Vector for Cancer Immunotherapy |
title_sort | listeria monocytogenes as a vector for cancer immunotherapy |
topic | Editorial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563333/ https://www.ncbi.nlm.nih.gov/pubmed/32764358 http://dx.doi.org/10.3390/vaccines8030439 |
work_keys_str_mv | AT leitaojorgeh listeriamonocytogenesasavectorforcancerimmunotherapy |